コラテジェン市場：市場規模、予測、市場洞察-2032年

コラテジェン（HGFプラスミド）は再生医療製品であり、その主成分はHGFのcDNAを含む5181塩基対のHGF遺伝子をコードするプラスミドDNA（Beperminogene Perplasmid）です。閉塞性動脈硬化症（ASO）またはバージャー病のCLIを治療することを目的としています。医薬品と同様に薬理学的治療効果を期待して開発されました。コラテジェンを虚血部位近傍の筋肉に注射することで、HGF産生・放出による血管新生を誘導し、血管数と血流を増加させることで虚血肢の状態を改善することが期待されます。ASOやバージャー病患者の重症四肢虚血の治療薬と考えられています。

遺伝子治療は、患者の体内に遺伝子を導入し、コード化されたタンパク質が標的疾患に対して有利に働くように誘導するものです。1980年代後半には、次世代の医療として注目されるようになっています。肝細胞の成長を助けるタンパク質である肝細胞増殖因子（HGF）は、血管の成長も促進します。

今後数年間で、末梢動脈疾患（PAD）の市場シナリオは、世界中の広範な調査と医療支出の増加により変化します。各社は、病状を治療/改善するための新たなアプローチに焦点を当てた治療法を開発し、課題を評価し、コラテジェンの優位性に影響を与える可能性のある機会を模索しています。PADのための他の新興製品がコラテジェンに厳しい市場競争を与えると予想され、近い将来、後期新興治療薬の発売が市場に大きな影響を与えるとみられています。

当レポートでは、日本における末梢動脈疾患（PAD）治療薬のコラテジェン市場について調査し、市場の概要とともに、競合情勢、2032年までの市場規模予測、SWOT分析などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 PADにおけるコラテジェンの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• 規制のマイルストーン
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 コラテジェン市場評価

• PADにおけるコラテジェン市場の見通し
• 日本分析
  • 日本におけるPAD治療薬コラテジェンの市場規模

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: COLLATEGENE, Clinical Trial Description, 2023
• Table 2: COLLATEGENE, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Late-stage Emerging Therapies)
• Table 5: COLLATEGENE Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: COLLATEGENE Market Size in Japan, USD million (2019-2032)

"COLLATEGENE Market Size, Forecast, and Market Insight - 2032" report provides comprehensive insights about COLLATEGENE for Peripheral Artery Disease (PAD) in Japan. A detailed picture of the COLLATEGENE for PAD in Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the COLLATEGENE for PAD. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the COLLATEGENE market forecast analysis for PAD in Japan, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in PAD.

Drug Summary:

COLLATEGENE (HGF plasmid) is a regenerative medical product, and its main component is a plasmid DNA encoding the HGF gene of 5181 base pairs, containing the cDNA for HGF (Beperminogene Perplasmid). It is intended to treat the CLI of arteriosclerosis obliterans (ASO) or Buerger's disease. It was developed with an expectation of its pharmacological therapeutic effects, as with pharmaceuticals. COLLATEGENE administered by injection into muscles near the ischemic focus is expected to induce angiogenesis through HGF production/release and improve the ischemic state of the limb by increasing the number of blood vessels and blood flow. It is considered therapeutic in treating critical limb ischemia in patients with ASO or Buerger's disease.

Gene therapy introduces genes to a patient's body to guide encoded proteins to work favorably against targeted diseases. In the late 1980s, it became the next generation in medicine. Hepatocyte growth factor (HGF), a protein to help grow hepatocytes, also promotes the growth of blood vessels.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the COLLATEGENE description, mechanism of action, dosage and administration, research and development activities in Peripheral Artery Disease (PAD).
• Elaborated details on COLLATEGENE regulatory milestones and other development activities have been provided in this report.
• The report also highlights the COLLATEGENE research and development activities in PAD across Japan.
• The report also covers the patents information with expiry timeline around COLLATEGENE.
• The report contains forecasted sales of COLLATEGENE for PAD till 2032.
• Comprehensive coverage of the late-stage emerging therapies for PAD.
• The report also features the SWOT analysis with analyst views for COLLATEGENE in PAD.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

COLLATEGENE Analytical Perspective by DelveInsight

• In-depth COLLATEGENE Market Assessment

This report provides a detailed market assessment of COLLATEGENE for Peripheral Artery Disease (PAD) in Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• COLLATEGENE Clinical Assessment

The report provides the clinical trials information of COLLATEGENE for PAD covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Peripheral Artery Disease (PAD) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence COLLATEGENE dominance.
• Other emerging products for PAD are expected to give tough market competition to COLLATEGENE and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of COLLATEGENE in PAD.
• Our in-depth analysis of the forecasted sales data of COLLATEGENE from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the COLLATEGENE in PAD.

Key Questions:

• What is the product type, route of administration and mechanism of action of COLLATEGENE?
• What is the clinical trial status of the study related to COLLATEGENE in Peripheral Artery Disease (PAD) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the COLLATEGENE development?
• What are the key designations that have been granted to COLLATEGENE for PAD?
• What is the forecasted market scenario of COLLATEGENE for PAD?
• What are the forecasted sales of COLLATEGENE in Japan?
• What are the other emerging products available and how are these giving competition to COLLATEGENE for PAD?
• Which are the late-stage emerging therapies under development for the treatment of PAD?

Table of Contents

1. Report Introduction

2. COLLATEGENE Overview in PAD

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestones
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. COLLATEGENE Market Assessment

• 5.1. Market Outlook of COLLATEGENE in PAD
• 5.2. Japan Analysis
  • 5.2.1. Market Size of COLLATEGENE in Japan for PAD

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options